Self-hypnosisNCT06493097
Hypnotherapy With Audiofiles for Children and Adolescents With Disorders of Gut-brain Interactions in Sweden -a Feasibility Study
A study testing Gut-directed hypnotherapy via audio files in people with Self-hypnosis and Functional Bowel Disorder, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
This study aims at testing the effect and feasibility of a new treatment strategy - hypnotherapy mediated with audio files - for children and adolescents with disorders of gut-brain-interaction (DGBI) in Sweden. Read more about this study
- Who is it for?
- Ages 8 to 17 years
- Conditions the study is for
- Self-hypnosis, Functional Bowel Disorder, Functional Abdominal Pain Syndrome
- What is being tested?
- Gut-directed hypnotherapy via audio files
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteSweden
- Study dates
- 1 Oct 2023to 30 Aug 2024
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Diagnosis: irritable bowel syndrome, functional abdominal pain, functional dyspepsia (following the Rome IV diagnostic criteria)
- The participant and at least one of the parents must understand Swedish
Who cannot join
- other medical condition that better explains the symtoms
- Absence from school >40% and/or psychiatric diagnosis that is judged to be more primary than the gastrointestinal problems, in these cases the children/young people are judged to need more intensive and multi-professional treatment
Trial locations and contacts
1 site in 1 country.
About this study
This study aims at testing the effect and feasibility of a new treatment strategy - hypnotherapy mediated with audio files - for children and adolescents with disorders of gut-brain-interaction (DGBI) in Sweden. The treatment protocol has been used and studied in Netherlands, but the investigators have translated and formed it to suit the Swedish population. This study is a feasibility study that is followed by a large RCT to compare different psychological treatment options for this patient group.
If hypnotherapy mediated via audio files proves to be effective and feasible for this patient group, it would mean:
- An exponential increase in the availability of evidence-based treatments. The hypnotherapy treatment is markedly easier to distribute than e.g. cognitive behavior therapy (CBT) which requires chat contact with a psychologist and is made available regardless of where in Sweden the family lives. In addition to shortened waiting times for patients, this would decrease the pressure in somatic care.
- Possibility to offer tailored treatments. No treatment works for everyone. It is reasonable to assume that treatments with such different focuses as hypnotherapy and exposure-based CBT may be differently effective for different patients. A new treatment option can help a larger proportion of patients.
- A more cost-effective treatment. Gut-directed hypnotherapy with audio files is a very inexpensive treatment, which would likely result in significant cost savings for this patient population.
Read the detailed description
Hypnotherapy has shown promising results in international studies for treatment of DGBI. Gut-directed hypnotherapy for children is based on relaxation and imagery and sensation exercises with a focus on gastrointestinal symptoms ("directed daydreams", which both divert and provide a pleasant feeling in the body, which the child can use when the symptoms come). The aim is to both improve awareness of and increase control over the symptoms. Hypnotherapy is a safe treatment that has been shown to have minimal side effects. The research group in the Netherlands with whom investigators collaborate in this project has shown a significantly better effect in short and long term with hypnotherapy than with conventional medical treatment for children and adolescents with DGBI. Hypnotherapy via home-based self-exercises with audio files is proven as effective as individual therapy performed face-to-face by a therapist.
Preliminary results/ backround work: Collaboration with the Dutch group started, the treatment manual for gut-directed hypnotherapy has been translated into Swedish and has undergone cultural validation by experienced child psychologists and has been recorded in audiobook quality. The study website (where the families have access to the treatments and measure the outcomes) has been created. Comprehensive patient information material has been created about DGBI and hypnotherapy, which consists of both texts, films, and audio to reach all patient types (Fig 1a-b). The pilot study is ongoing since Sep 2023.
Aim: To test the practical aspects concerning patient recruitment, information about treatment, the treatment itself, measurement of outcome, required power for the main outcome. The lessons learned will help investigators to fine-tune the protocol and give the planned large RCT optimal conditions.
Study population: 30 patients (8-17 years, of which approximately half are 13-17 years) from Sachsska Children's Hospital's Gastrointestinal Clinic and Pediatric and Adolescent Medical Clinics in Stockholm, who are diagnosed with DGBI following Rome IV criteria. Before inclusion, the families meet with a study physician and a study nurse for an assessment of inclusion and exclusion criteria, for information about the study, and review of treatment principles.
Exposure: Gut-directed hypnotherapy exercises 5 times/week, for 12 weeks, delivered via audio files on the study's website (files can also be downloaded to mobile phone).
Outcome: At the beginning and end of the treatment and every third week during the treatment, the patients and parents will fill in self-assessments in the form of internationally validated questionnaires for symptom severity, quality of life, school absence etc, via an internet platform with identification control (which we have worked with in many previous projects). Improvement by >30% on the primary outcome measure is defined as clinically significant, based on international recommendations.
Power: In several previous pilot studies, 30 patients have been sufficient to obtain meaningfully tight confidence intervals for the outcome measures and to be able to conclude for future RCTs. However, no formal power analysis is relevant without a comparison group.
- Being tested
- Gut-directed hypnotherapy via audio files
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gut-directed hypnotherapy via audio filesBehavioural
5 audio files 10-15 min each, min 5 times a week for 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Treatment with hypnotherapy audio files | Experimental | Participants get access to a website, where they can find information about the diagnosis DGBI and mechanisms leading to symtoms. On the website they also get access to a tretament protocoll for self-hypnosis with audio files (5 different audio files, age-adjusted). Participants listen to audio files min 5 times/week for 12 weeks. They answer the study questionnaries before, after and every 3 weeks during the treatment. Receives: Behavioral: Gut-directed hypnotherapy via audio files |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peds-QL-gastro
Short questionnaire gastrointestinal symptom scale. Minimum value 0, maximum value 100, higher score means better outcome.
Measured: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Secondary outcomes (6)
Pain Frequency and Intensity
FACES pain scale. Minimum value 0, maximum value 10, higher score means worse outcome.
Measured: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Stress
PAS pediatric stress questionnare. Minimum value 0, maximum value 44, higher score means worse outcome.
Measured: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Gastrointestinal Symtom -Related Anxiety
BRQ-C questionnare. Minimum value 11, maximum value 77, higher score means worse outcome.
Measured: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
GI Symptom Specific Anxiety
Visceral sensitivity index short scale. Minimum value 0, maximum value 35, higher score means worse outcome.
Measured: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Quality of Life
Peds-QL- QOL. Minimum value 0, maximum value 100, higher score means better outcome.
Measured: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Adequate Relief
SAQ. Minimum value 0, maximum value 7, higher score means better outcome.
Measured: Week 12 (post) treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2024
- Study start1 Oct 2023
- Primary completion30 Jun 2024
- Study completion30 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Self-hypnosisStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Region Stockholm
- Responsible party
- Principal investigator, Ola Olen, Karolinska Institutet
- Investigators
- Ola Olén, MD PhD prof, Principal investigator, Department of clinical epidemiology, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06493097
- Sponsor's protocol ID
- 2023-00296-01
- Other IDs
- 2023
- Status last verified
- Dec 2025
- First submitted
- 25 Jun 2024
- Last updated
- 30 Jan 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No